Financials in GBp. Standardized financial statements.
A compact view of how Arecor Therapeutics plc turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £1.71M | £5.05M | £4.57M | £2.40M | £1.16M | £1.70M | £1.89M | £747,672 | £1.35M |
| Revenue Growth? | -66.1% | +10.5% | +90.3% | +107.5% | -31.8% | -10.2% | +152.9% | -44.6% | 0.0% |
| Cost of Revenue? | £663,000 | £3.51M | £3.32M | £341,000 | £0 | £0 | £0 | £0 | £0 |
| Gross Profit? | £1.05M | £1.54M | £4.57M | £2.40M | £1.16M | £1.70M | £1.89M | £747,672 | £1.35M |
| Gross Margin? | +61.3% | +30.5% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | £5.65M | £12.24M | £13.75M | £12.91M | £7.13M | £5.13M | £4.58M | £3.60M | £2.75M |
| Operating Income? | -£4.60M | -£10.70M | -£9.18M | -£11.66M | -£5.98M | -£3.43M | -£2.69M | -£2.85M | -£1.40M |
| EBITDA? | -£4.39M | -£10.15M | -£8.39M | -£10.06M | -£6.27M | -£3.26M | -£2.61M | -£2.68M | -£1.22M |
| Income Before Tax | £994,000 | -£10.62M | -£8.90M | -£10.54M | -£6.95M | -£3.51M | -£2.69M | -£2.87M | -£1.43M |
| Income Tax Expense | £62,000 | -£382,000 | -£347,000 | -£1.28M | -£776,000 | -£759,968 | -£502,287 | -£435,090 | -£306,998 |
| Net Income? | £664,000 | -£10.24M | -£8.55M | -£9.26M | -£6.17M | -£2.75M | -£2.19M | -£2.44M | -£1.12M |
| EPS? | £0.02 | £-0.31 | £-0.28 | £-0.32 | £-0.27 | £-0.10 | £-0.08 | £-0.09 | £-0.04 |
| Diluted EPS? | £0.02 | £-0.31 | £-0.28 | £-0.32 | £-0.27 | £-0.10 | £-0.08 | £-0.09 | £-0.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality